Skip to main content

David Asher Leiman

Associate Professor of Medicine
Medicine, Gastroenterology

Overview


Dr. Leiman is an Associate Professor of Medicine and gastroenterologist specializing in esophageal diseases and swallowing disorders, such as eosinophilic esophagitis (EoE), motility disorders such as achalasia, and gastroesophageal reflux disease (GERD) as well as its associated complications including Barrett’s esophagus (BE). His busy clinical practice dovetails with his academic focus on health services research, including patient outcomes and clinical quality measurement. He is also a PI for several ongoing multicenter clinical trials investigating novel therapies for EoE and GERD.

Dr. Leiman has mentored numerous medical students, residents, and GI fellows on research and quality improvement projects resulting in research awards, presentations at national meetings, and peer-reviewed publications.

Current Appointments & Affiliations


Associate Professor of Medicine · 2023 - Present Medicine, Gastroenterology, Medicine
Member in the Duke Clinical Research Institute · 2017 - Present Duke Clinical Research Institute, Institutes and Centers
Member of the Duke Cancer Institute · 2018 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published October 13, 2022
Expert Perspectives on PPI Prescribing & Monitoring Patterns
Published June 1, 2022
Many Studies of Digestive Diseases Fail to Examine Food Insecurity

View All News

Recent Publications


Clinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.

Journal Article Gastroenterol Clin North Am · March 2026 Barrett's esophagus (BE) is a major risk factor for the development of esophageal adenocarcinoma (EAC) and is the only known precursor lesion for this lethal cancer. Although BE is relatively common among patients with gastroesophageal reflux disease, most ... Full text Link to item Cite

Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.

Journal Article Am J Gastroenterol · February 25, 2026 BACKGROUND AND AIMS: The adjunctive use of p53 immunohistochemistry (IHC) has been proposed as a potential tool to improve risk stratification in Barrett's esophagus (BE) with conflicting results. We performed a systematic review and meta-analysis to evalu ... Full text Link to item Cite
View All Publications

Recent Grants


Dupixent Registry R668-EE-2328 EDESIA Pro00117064

Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2025 - 2030

View All Grants

Education


Vanderbilt University, School of Medicine · 2009 M.D.